VRTX - VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES | Benzinga
- Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes
- TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells
BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
"Our goal is to transform the treatment of T1D, and our stem cell-derived, fully differentiated islet cell VX-880 Ph 1/2 program has demonstrated this potential," said Morrey Atkinson Ph.D., Executive Vice President, Chief ...